The Vanguard Group, Inc. recently announced the acquisition of new stake in Edwards Lifesciences Corp (NYSE:EW). The institutional investor has increased its shareholding in the Healthcare company by 0.62% to 49.08 million shares with purchase of 0.3 million shares. This fresh investment now brings its stake to 8.09% valued currently at $3.32 billion. In addition, BlackRock Fund Advisors raised its holdings by 0.3 million to 31.56 million shares. And Capital Research & Management Co has lifted its position by 11.99% or 3.24 million shares – to 30.25 million shares.
Currently, there are 608.30M common shares owned by the public and among those 597.53M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 205 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 90 of these insider trades were purchases, accounting for 1,455,193 shares. Insider sales of the common stock occurred on 115 occasions, with total insider shares sold totaling 1,296,234 shares.
The top 3 mutual fund holders in Edwards Lifesciences Corp are Vanguard Total Stock Market ETF, Vanguard 500 Index Fund, and Vanguard Health Care Fund. Vanguard Total Stock Market ETF owns 19.03 million shares of the company’s stock, all valued at over $1.29 billion. The company bought an additional 82040.0 shares recently to bring their total holdings to about 3.14% of the shares outstanding. Vanguard 500 Index Fund bought 73868.0 shares to see its total holdings expand to 14.68 million shares valued at over $994.25 million and representing 2.42% of the shares outstanding. Vanguard Health Care Fund sold -0.28 million shares to bring its total holdings to over 9.39 million shares at a value of $635.53 million. Vanguard Health Care Fund now owns shares totaling to 1.55% of the shares outstanding.
However, the script later moved the day high at 76.08, up 0.57%. The company’s stock has a 5-day price change of 4.34% and 4.67% over the past three months. EW shares are trading 0.94% year to date (YTD), with the 12-month market performance up to 3.15% higher. It has a 12-month low price of $60.57 and touched a high of $94.87 over the same period. EW has an average intraday trading volume of 4.77 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.66%, 10.04%, and -4.80% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 84.96% of the company’s 608.30M shares outstanding. Mutual fund holders own 36.09%, while other institutional holders and individual stakeholders account for 49.78% and 1.16% respectively.
It has a market capitalization of $45.68B and a beta (3y monthly) value of 1.04. The stock’s trailing 12-month PE ratio is 32.20, while the earnings-per-share (ttm) stands at $2.34. The company has a PEG of 4.03 and a Quick Ratio of 2.45 with the debt-to-equity ratio at 0.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.26% over the week and 2.62% over the month.
Analysts forecast that Edwards Lifesciences Corp (EW) will achieve an EPS of $0.64 for the current quarter, $0.66 for the next quarter and $2.77 for 2024. The lowest estimate earnings-per-share for the quarter is $0.62 while analysts give the company a high EPS estimate of $0.66. Comparatively, EPS for the current quarter was $0.64 a year ago. Earnings per share for the fiscal year are expected to increase by 1.18%, and 10.25% over the next financial year. EPS should shrink at an annualized rate of 7.99% over the next five years, compared to 22.06% over the past 5-year period.
